衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Fibulin 3 (FBLN3) ,etc. by FLIA (Flow Luminescence Immunoassay)
EFEMP1; DHRD; DRAD; FBNL; MLVT; MTLV; S1-5; EGF-Containing Fibulin-Like Extracellular Matrix Protein 1; Fibrillin-Like; Extracellular protein S1-5
（注：單次混測多因子不超過8個指標(biāo) ）
- 編號ULMF422Ra
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時長3.5h
- 檢測范圍0.05-50ng/mL
- 靈敏度最小可檢測劑量小于等于0.017 ng/mL.
- 樣本類型Serum, plasma, tissue homogenates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價格 ¥ 1423 ¥ 1477 ¥ 1560 ¥ 1669 ¥ 1778 ¥ 1943 ¥ 2189 ¥ 2736 添加到價格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測定并計(jì)算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 90-105 | 101 |
| EDTA plasma(n=5) | 83-97 | 86 |
| heparin plasma(n=5) | 83-91 | 88 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 97-104% | 81-97% | 78-90% | 85-99% |
| EDTA plasma(n=5) | 84-98% | 81-98% | 94-105% | 97-105% |
| heparin plasma(n=5) | 83-96% | 78-101% | 86-103% | 97-105% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠）標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，
37°C酶標(biāo)板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測溶液A100μL，37°C酶標(biāo)板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測溶液B100μL，37°C振動孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPF422Ra01 | 衰老關(guān)鍵蛋白3(FBLN3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAF422Ra01 | 衰老關(guān)鍵蛋白3(FBLN3)多克隆抗體 | IHC |
| USEF422Ra | 衰老關(guān)鍵蛋白3(FBLN3)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMF422Ra | 衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| 1 | Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma [PubMed: PMC3761217] |
| Anticancer Res. | YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis. [Pubmed: 24324091] |
| Oncology Reports | Role of fibulin-3 in lung cancer: In vivo and in vitro analyses [Spandidos-publications: Source] |
| Current Pulmonology Reports | Discovery of new biomarkers for malignant mesothelioma [Springer:Source] |
| United States Patent Application 20140378336 | DIAGNOSIS OF CELL PROLIFERATIVE DISEASES [Freepatentsonline:Source] |
| Thorax. | Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma [Pubmed:Pmc4174124] |
| Egyptian Journal of Chest Diseases and Tuberculosis | Value of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusions [Pubmed:23050525] |
| Radiol Oncol | Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma [PubMed: 26401134] |
| British Journal of Cancer | Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis [PubMed: 26263483] |
| J Thorac Oncol. | Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. [Pubmed:26903362] |
| BMJ Open | Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study [pubmed:27884852] |
| 25 | HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients [pubmed:26733616] |
| BMJ Journals | Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational … [e013324.abstract] |
| Anticancer Res. | Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma. [pubmed:28314308] |
| Dis Markers. | A Novel Panel of Serum Biomarkers for MPM Diagnosis. [pubmed:28348450] |
| The Knee | Association of fibulin-3 concentrations with the presence and severity of knee osteoarthritis: A cross-sectional study [pubmed:29195846] |
| Disease markers | Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population [pubmed:29200597] |
| Molecular?Medicine?Reports | Placental protein 14 as a potential biomarker for diagnosis of preterm premature rupture of membranes [Pubmed:29749501] |
| Oncotarget | The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion [Pubmed:30046386] |
| Advances in?Clinical?and Experimental?Medicine | Fibulin-3 and other cartilage metabolism biomarkers in relationship to calprotectin (MRP8/14) and disease activity in rheumatoid arthritis patients treated with?… [68362.pdf] |
| PLoS One | Prediction of pneumoconiosis by serum and urinary biomarkers in workers exposed to asbestos-contaminated minerals [Pubmed: 30946771] |
